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Abstract 
 Clostridioides (formerly Clostridium) difficile is a Gram-positive anaerobic bacterial pathogen that 
causes severe gastrointestinal infection in humans. The current chemotherapeutic options are vastly inadequate, 
expensive and limited; this results in an exorbitant medical and financial burden. New, inexpensive 
chemotherapeutic treatments for C. difficile infection with improved efficacy are urgently needed.   A streamlined 
synthetic pathway was developed to allow access to 38 novel mono- and di-cationic biaryl 1,2,3-triazolyl 
peptidomimetics with increased synthetic efficiency, aqueous solubility and enhanced antibacterial efficacy. The 
monocationic arginine derivative 28 was identified as a potent, Gram-positive selective antibacterial with MIC 
values of 4 µg/mL against methicillin-resistant Staphylococcus aureus and 8 µg/mL against C. difficile. 
Furthermore, the dicationic bis-triazole analogue 50 was found to exhibit broad-spectrum activity with substantial 
Gram-negative efficacy against Acinetobacter baumannii (8 µg/mL), Pseudomonas aeruginosa (8 µg/mL) and 
Klebsiella pneumoniae (16 µg/mL); additionally, compound 50 displayed reduced haemolytic activity (<13%) in 
an in vitro haemolysis assay. Membrane-disruption assays were conducted on selected derivatives to confirm the 
membrane-active mechanism of action inherent to the synthesized amphiphilic compounds. A comparative 
solubility assay was developed and utilized to optimize the aqueous solubility of the compounds for in vivo studies. 
The biaryl peptidomimetics 28 and 67 were found to exhibit significant efficacy in an in vivo murine model of C. 
difficile infection by reducing the severity and slowing the onset of disease.  
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 Clostridioides (formerly Clostridium) difficile is a Gram-positive, anaerobic bacterium that causes mild 
to serious infections in the gastrointestinal (GI) tract due to the potent toxins and resilient endospores that are 
produced by the organism [1-2]. C. difficile infection (CDI) occurs when the normal GI microbiota is 
compromised by conventional antibiotics; this allows C. difficile to flourish in the GI tract due to the absence of 
the usual enteric microbiome [1-2]. Broad spectrum antibiotic therapy indiscriminately destroys the GI microflora, 
but fails to eradicate C. difficile spores [3]; this unwanted side-effect allows C. difficile to infect up to 20% of 
hospital patients administered oral antibiotics [1]. C. difficile produces robust endospores that are resistant to most 
antibiotics, alcohol-based hand sanitizers, heat and freezing [3]. The hospital setting provides a prime ‘breeding 
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ground’ for C. difficile spores, which can stay viable for months at a time [1-2].  Almost all broad-spectrum 
antibiotics can instigate CDI by eliminating the commensal GI microflora; however, antibiotics such as 
ampicillin/amoxicillin, cephalosporins, clindamycin and fluoroquinolones are most commonly associated with 
CDI [1]. 
 
CDI exhibits an overall mortality rate of up to 8% [2] and infection recurrence occurs in up to 20% of cases treated 
with first-line chemotherapeutics (i.e. vancomycin or metronidazole) [4]. Both the severity and incidence of CDI 
cases has increased in the last decade due to epidemics of hypervirulent C. difficile strains, e.g. PCR ribotype 027 
– also known as strain B1/NAP1/027 [1-2]. This ribotype exhibits a mortality rate that is three times higher than 
normal C. difficile isolates [1]. The prevalence of C. difficile infection results in a massive financial burden on the 
modern healthcare system (≤$4.8 billion per annum) [5]. The CDC issued a report in 2013 entitled ‘Antibiotic 
Resistance Threats’; C. difficile was listed as the number one bacterial threat facing the healthcare sector and 
humans in general.[6] A recent update by the CDC reports that CDI is responsible for approximately 500,000 
infections and 15,000 deaths annually in the USA – the highest of any of the bacterial threats listed by the CDC 
[5]. Due to the high levels of infection, recurrence, mortality, cost and the lack of adequate treatments for CDI, 
there exists a substantial incentive to pursue novel chemotherapeutics that effectively combat CDI. 
Antibacterial selectivity for C. difficile is an essential component for a fully effective CDI chemotherapeutic. The 
elimination of all GI bacteria by broad-spectrum antibacterial activity provides an ideal habitat for C. difficile 
spores to grow; therefore, the maintenance and/or restoration of commensal GI microflora is essential for 
preventing CDI recurrence [1-3].  Fecal transplantation has thus become a viable method for treating cases of 
chronic/severe CDI, as it physically replaces the commensal GI microflora [1-2, 7]. The classic chemotherapeutic 
treatments for CDI (i.e. vancomycin and metronidazole) suffer from efficacy issues, most notably CDI recurrence, 
due to their lack of selectivity for C. difficile and inability to prevent sporulation [1-2]. 
Fidaxomicin was approved by the FDA in 2011 and it is the only new small-molecule chemotherapeutic that has 
been specifically approved for use against CDI [8]; it exhibits approximately 50% less CDI recurrence relative to 
vancomycin [9]. Furthermore, the increased efficacy of fidaxomicin is thought to be a result of its selectivity for 
C. difficile over commensal enteric microflora (i.e. Bacteroides spp.) and its ability to reduce C. difficile 
sporulation [3, 10]. There are numerous potential chemotherapeutics undergoing clinical trials for use in the 
treatment of CDI; examples include CRS3123 (National Institute for Allergy and Infectious Disease) [4, 11-12], 
LFF571 (Novartis) [13-16], NVB302 (Novacta Biosystems) [4, 3, 17], ridinilazole (Summit Pharmaceuticals) 
[18-19] and cadazolid (Actelion Ltd.) [20-22]. Many other small molecule chemotherapeutics are currently under 
investigation for use in the battle against C. difficile, such as various synthetic derivatives of purines [23], 
macrolides [24], nitroheterocycles [25], glycopeptides [26], tetramic acids [27], antimicrobial peptidomimetics 
[28-29], nylon-3 polymers [30] and bis-indoles [31]. Immunotherapeutic approaches include vaccination and 
passive antibody therapy; so far, these therapies have all focused on the C. difficile toxins. There are two vaccines 
currently being independently investigated in clinical trials by Pfizer and Intercell [3]. In October 2016, 
bezlotoxumab (Merck’s monoclonal antibody targeting C. difficile toxin B) was given FDA approval as an adjunct 
therapy for patients who are currently undergoing antibiotic therapy for CDI treatment and are at high risk of 
recurrent infection [32]. There exists a drastic need for more efficacious chemotherapeutics for the treatment of 
CDI; a well-tolerated and safe medication that could selectively target C. difficile (and its spores), while leaving 
the enteric microbiome intact, would prove invaluable in the treatment of severe and recurrent CDI.  
Recent work in our laboratory has generated a class of cationic amphiphilic biarylpeptidomimetics (e.g. lead 





Fig. 1. Lead peptidomimetic compound 1. 
These membrane-active peptidomimetic derivatives exhibit potent broad-spectrum activity against Gram-positive 
and Gram-negative pathogenic bacteria (Fig. 1) [28-29]. Previous reports have shown that the major 
pharmacophore components required for antimicrobial activity are a biaryl aromatic core with attached cationic 
residues and hydrophobic residues [29, 28, 33-35]. This pharmacophore model parallels other antimicrobial 
peptide mimic models, like those proposed by Haldar et al. [36] and Kumar et al. [37]. The mixture of cationic 
and hydrophobic residues attached to the scaffold backbone confers an amphiphilic conformation to the 
molecules, which is essential for membrane disruption and antibacterial activity. Prior work has furnished multiple 
1,2,3-triazole containing amphiphilic peptidomimetics with strong activity against C. difficile (MIC = 4 µg/mL) 
[28-29]; these biarylpeptidomimetics were investigated as potential CDI treatments due to their potential low oral 
bioavailability and promising in vitro activity against C. difficile [29]. 
Utilizing lead compound 1 as a starting point and the established pharmacophore as a guide, three new series of 
amphiphiles were developed to allow for facile synthetic access to novel biaryl 1,2,3-triazole peptidomimetics for 
investigation as potential CDI chemotherapeutics. A simplified synthetic pathway was designed and utilized to 
obtain 38 final antibiotic derivatives which were subjected to in vitro antibacterial activity testing against a range 
of Gram-positive and Gram-negative pathogenic bacteria. Membrane disruption (i.e. cytoplasmic membrane 
depolarization and permeabilization) assays were performed on prototypical derivatives to confirm their mode of 
action. In vitro haemolysis and cytotoxicity assays were also performed on specific derivatives. A comparative 
solubility assay was designed and utilized to investigate the relative aqueous solubility of the peptidomimetics for 
in vivo administration. Selected peptidomimetics from this study and previous studies [29, 28] were then subjected 
to a murine in vivo C. difficile infection model to ascertain their viability as chemotherapeutic agents for the 
treatment of CDI. Preliminary pharmacokinetics analysis of the mouse blood and feces was conducted to verify a 
lack of systemic absorption.  
2. Results and Discussion 
2.1 Design, synthesis and characterization of cationic biaryl peptidomimetic amphiphiles 
Three series of cationic biaryl 1,2,3-triazolyl amphiphiles were designed and synthesized for antibacterial 
evaluation as potential C. difficile chemotherapeutics: monocationic amide analogues (A), dicationic amide 
analogues (B) and dicationic bis-triazole derivatives (C) (Fig. 2). 
 
Fig. 2. General structures of the cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles (Series A, B and C). 
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In an attempt to streamline synthetic access to the amphiphilic derivatives, a modified backbone structure was 
developed based upon lead compound 1, previous studies [29, 33-35, 38-39] and the known pharmacophore 
requirements. It was envisioned that a reversed peptide orientation (Fig. 3) would allow for a shorter synthetic 
pathway without compromising antibacterial efficacy. 
 
Fig. 3. Comparison of the previous synthetic pathway A (6× steps) [28] and current synthetic pathway B (3× 
steps); note the variation in the resultant peptide backbone orientation. 
 
In order to furnish a library with enhanced structural diversity, variation of the biaryl core (i.e. (S)-binaphthyl or 
biphenyl), cationic amino acid residues (i.e. Lys and/or Arg) and the hydrophobic termini linker (i.e. amide or 
1,2,3-triazole) were undertaken to obtain the different amphiphilic derivatives of Series A, B and C. Unnatural D-
configured amino acids were utilized for enhanced metabolic stability against proteases in the mammalian GI tract 
[40]. An overview of the modular synthetic pathway is exemplified in Scheme 1; a small pool of key precursor 
building blocks were combined via copper-catalysed azide-alkyne cycloaddition (CuAAC) and peptide coupling 
reactions to furnish the desired scaffolds (e.g. compounds 4 and 5). These scaffolds served as divergence points 
in the synthetic pathway; multiple antimicrobial peptidomimetics were thus obtained through facile derivatization 
of the corresponding scaffolds via CuAAC or peptide coupling reactions followed by acidolytic side-chain N-




Scheme 1. Example of the modular synthetic pathway utilized to achieve Series A and Series C derivatives. 
The required azido amine fragments were synthesized from commercially available N-Fmoc-D-amino acids. The 
N-Fmoc amino acids (6 and 7) were reduced to their corresponding alcohols (8 and 9) [41] via mixed anhydride 
reduction with NaBH4 [42] (Scheme 2). Initially, azido amine 10 [29] was realized by mesylation of alcohol 8 
followed by azidation in DMF (Scheme 2); unfortunately, the amine was obtained in lower yields due to 
competing oxazolidinone formation during the azidation step. To avoid this issue during the synthesis of azido 
amine 11, the reported procedure [29] was followed with slight modification; the iodide intermediate was 
subjected to SN2 displacement with NaN3 at 20 °C before raising the temperature to 50 °C to promote N-Fmoc 
deprotection [43], thus preventing the possibility of oxazolidinone formation (Scheme S1). Chromatographic 
purification of the amine product was eliminated in favour of an acid/base isolation procedure.  
 
Scheme 2. Synthesis of azido amines 10 and 11. Reagents and conditions: (a) CH3SO2Cl (1.5 eq), NEt3 (1.5 eq), CH2Cl2, 
0 °C (15 min)  rt (1 h); (b) NaN3 (5.0 eq), DMF, 50 °C (18 h); (c) I2 (1.1 eq), PPh3 (1.1 eq), imidazole (1.2 eq), CH2Cl2, rt 
(20 h); (d) NaN3 (5.0 eq), DMF, 20 °C (4 h)  50 °C (18 h).  
 
With the required precursors in hand, the Series A scaffold acids (16–19) were then constructed by CuAAC 
reaction between an (S)-binaphthyl or biphenyl alkyne core (12 or 13) [28] and an azido acid component (14 or 
15) [28] (Scheme 3). Analysis of the gHMBC NMR spectrum of scaffold derivative 28 allowed for unequivocal 





Scheme 3. Synthesis of Series A scaffold acids 16–19 by CuAAC reaction. 
When the 13C NMR spectra of the scaffold acids 16–19 were acquired in CDCl3 or CD3OD, the triazole carbons 
and the adjacent methine and carboxyl carbons (Fig. 4) could not be assigned to a corresponding resonance; the 
use of 2-D NMR (i.e. gHMBC and/or gHSQC) and/or DMSO-d6 was necessary to properly assign the carbon 
resonances. Furthermore, the 1H NMR resonances assigned to the methine and triazole protons were often 
extremely broad or completely unobservable without 2-D NMR analysis. Inter- or intra-molecular hydrogen 
bonding between the carboxylic acid functionality and the internal triazole moiety was the likely cause behind 
this NMR phenomena, as the anomalies were not observed amongst the amide derivatives of the scaffold acids.  
 
Fig. 4. a) General structure of scaffold acids that exhibited weak or non-observable NMR resonances; the affected carbons 
and protons are marked with red (· or H); b) Potential intramolecular hydrogen bonding (----) between the 1,2,3-triazole and 
the adjacent carboxylic acid moiety. 
Derivatization of the Series A scaffold acids (16–19) was thus accomplished by peptide bond formation with 
various hydrophobic amines (R-NH2) and EDCI/HOBt in CH3CN; subsequent N-deprotection of the cationic side-
chains with TFA/CH2Cl2/H2O followed by treatment with ethereal HCl yielded the Series A monocationic 
amphiphiles 20–39 (Table 1) as their hydrochloride salts.  
 
Table 1. Synthesis of the Series A monocationic amphiphiles. 
 
Entry Compound Aromatic Core AA·HCl R Yield(%)a 
1 20 Biphenyl Lys 
 
95 
2 21 Biphenyl Lys 
 
94 





4 23 Biphenyl Lys 
 
92 
5 24 Biphenyl Lys 
 
97 
6 25 Biphenyl Lys 
 
93 
7 26 Biphenyl Arg 
 
94 
8 27 Biphenyl Arg 
 
87 
9 28 Biphenyl Arg 
 
95 
10 29 Biphenyl Arg 
 
60 
11 30 Biphenyl Arg 
 
65 
12 31 Biphenyl Arg 
 
84 
13 32 Biphenyl Arg 
 
53 
14 33 Biphenyl Arg 
 
79 
15 34 Biphenyl Arg 
 
89 
16 35 Biphenyl Arg 
 
81 
17 36 Biphenyl Arg 
 
89 
18 37b Biphenyl Arg 
 
86 
19 38 (S)-Binaphthyl Arg 
 
87 
20 39 (S)-Binaphthyl Arg 
 
49 
a Yields are reported over two steps.  
b N,N-disubstituted amide: two -R groups. 
 
EDCI/HOBt peptide coupling of scaffold acid 18 with amino ester 40 [29] followed by base-promoted hydrolysis 
gave access to the Series B scaffold acid 41 (Scheme 4). The previously utilized two-step derivatization/side-
chain deprotection sequence was then employed to achieve the Series B dicationic amphiphiles 42–44 (Scheme 










Scheme 5. Synthesis of the Series B amide derivatives 42–44. 
 
The Series C scaffold azides 45–48 were assembled from scaffold acids 16–19 by EDCI/HOBt peptide coupling 
with the corresponding azido amine precursor (10 or 11) (Scheme 6). The resultant scaffold azides were then 
derivatized via CuAAC reaction and subjected to acidolytic side-chain N-deprotection to furnish the Series C 
dicationic amphiphiles 49–60 (Table 2) as their di-hydrochloride salts. 
 








Table 2. Synthesis of the Series C dicationic amphiphiles. 
 
Entry Compound Aromatic Core AA1·HCl AA2·HCl R Yield(%)a 
1 49 Biphenyl Lys Arg 
 
95 
2 50 Biphenyl Lys Arg 
 
85 
3 51 Biphenyl Lys Arg 
 
94 
4 52 Biphenyl Lys Arg 
 
90 
5 53 Biphenyl Arg Lys 
 
84 
6 54 Biphenyl Arg Lys 
 
94 
7 55 Biphenyl Arg Lys 
 
97 
8 56 Biphenyl Arg Lys 
 
90 
9 57 (S)-Binaphthyl Lys Arg 
 
56 
10 58 (S)-Binaphthyl Lys Arg 
 
75 
11 59 (S)-Binaphthyl Arg Lys 
 
95 
12 60 (S)-Binaphthyl Arg Lys 
 
68 
a Yields are reported over two steps. 
 
In addition to the three main series of synthesized antibacterial biaryl 1,2,3-triazolyl peptidomimetics (i.e Series 
A, B and C), a small subset of non-triazole amphiphiles (Series D) was synthesized for comparison to the triazole-
containing derivatives. The Series D scaffold acid 62 was obtained by EDCI/HOBt promoted peptide coupling 
reaction of acid 61 [34-35] with amino ester 40 [29] followed by ester hydrolysis with LiOH·H2O in THF/H2O 
(Scheme 7). The scaffold acid 62 was then subjected to the same sequential, two-step derivatization procedure 
utilized for the Series A and B derivatives to achieve the Series D amphiphiles 63–65 as hydrochloride salts 




Scheme 7. Synthesis of the Series D acid scaffold 62. 
 
Scheme 8. Synthesis of the Series D non-triazole derivatives 63–65. 
The 1H and 13C NMR spectra of specific amphiphilic derivatives (e.g. compound 23 – see Fig. S4 and S5) were 
found to exhibit rotameric resonance shouldering due to syn- and anti-amide and -carbamate rotamers (much akin 
to the previously synthesized cationic biaryl amphiphiles [28]). Evidence of rotameric entities amongst the biaryl 
peptidomimetics has previously been elucidated with variable temperature NMR experiments [28].  
Compound 28 was produced in >1 gram quantities for use in an in vivo murine C. difficile model; the purity was 
confirmed to be  >99% by reverse-phase analytical HPLC (Fig. S6). 
2.2. Antibacterial activity evaluation 
The synthesized peptidomimetic derivatives (Series A, B, C and D) were subjected to an antibacterial 
minimum inhibitory concentration (MIC) assay against a primary panel of Gram-positive pathogenic bacteria with 
vancomycin as a positive control; the MIC results are displayed in Tables 3–6. The compounds were then tested 
in an MIC assay against a secondary panel of Gram-negative pathogenic bacteria and MRSA at the Community 
for Open Antimicrobial Drug Discovery (CO-ADD) [44]. A cytotoxicity concentration (CC50) assay was also 
performed by CO-ADD; the synthesized compounds were tested at concentrations ≤32 µg/mL. Vancomycin, 
colistin and tamoxifen were used as positive controls in the Gram-positive, Gram-negative and cytotoxicity assays, 
respectively. The CO-ADD antibacterial activities and CC50 values from Series A, B, C and D are displayed in 
Tables 7–10, respectively. 
Initial MIC screening results indicated that reversal of the peptide backbone orientation to achieve a shorter 
synthetic pathway did not negatively impact the antibacterial efficacy of the amphiphilic molecules; both the 
monocationic (Series A) and dicationic (Series B and C) derivatives exhibited potent antibacterial activities 
against Gram-positive bacteria, with MIC values ranging from 2–16 µg/mL against S. aureus (Tables 3, 4 and 5). 
Amongst the monocationic Series A compounds, the arginine derivatives (26–39) were consistently more active 
against Gram-positive pathogens than their lysine counterparts (20–25) (Table 3). The monocationic (S)-
binaphthyl analogues 38 and 39 exhibited similar MIC values against the Gram-positive bacteria relative to their 
biphenyl counterparts 26 and 27 (i.e. within one MIC dilution). The arginine compound 28 was identified as the 
most potent monocationic derivative against C. difficile (MIC = 8 µg/mL) with strong activity against all other 
Gram-positive bacteria tested (MIC = 4 µg/mL) (Table 3). Most notably, C. difficile exhibited decreased 
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susceptibility to the monocationic compounds (26–39) relative to the other Gram-positive bacterial strains, 
displaying MIC values 2–8× fold less potent than the corresponding S. aureus MIC values (Table 3). Secondary 
MIC screening revealed that the monocationic derivatives lacked substantial activity against Gram-negative 
pathogens, with MIC values ≥32 µg/mL for virtually all Series A compounds that were tested (Table 7); these 
results were found to be in agreement with previous studies [28].  
The Series B dicationic amide analogues (42–44) displayed similar antibacterial efficacy against Gram-positive 
bacteria when compared to the monocationic Series A derivatives (Table 4). The presence of a second cationic 
residue endowed Gram-negative antibacterial efficacy to the cationic biaryl peptidomimetics, with MIC values of 
8 µg/mL against A. baumanii  and 16 µg/mL against K. pneumoniae and P. aeruginosa for the dicationic amide 
44 (Table 8). As previously indicated [28], the addition of a second cationic moiety allows for increased 
electrostatic attraction to the anionic bacterial membrane and a more optimal amphiphilic structure, which likely 
explains the observed general increase in antibacterial efficacy. 
Testing of the Series C dicationic bis-triazole derivatives (49–60) revealed potent antibacterial activity against 
both Gram-positive and Gram-negative bacterial pathogens (Tables 5 and 9, respectively). The Series C analogues 
displayed increased efficacy against C. difficile with MIC values of 8–16 µg/mL exhibited by the majority of the 
compounds tested. The biphenyl Series C analogues (e.g. compounds 49–56) displayed notably stronger 
antibacterial efficacy against Gram-negative bacteria than their (S)-binaphthyl counterparts (57–60) (Table 9); 
these results were in agreement with previous studies on related compounds [28]. The more soluble, less bulky 
biphenyl aromatic core may allow for easier penetration of the outer bacterial membrane to allow access to the 
cytoplasmic membrane, which could explain the increased efficacy observed against Gram-negative pathogens. 
Interestingly, the orientation of the two cationic residues was found to have little impact on antibacterial activity 
against Gram-positive pathogens (Table 5); however, the Lys-Arg orientation was markedly superior to the Arg-
Lys orientation (i.e. 2–4× more potent) for the Gram-negative species E. coli and A. baumannii (Table 9). 
Systematic variation on the hydrophobic termini was found to have a notable effect on the MIC values of the 
peptidomimetic amphiphiles; the least active Series A derivative was also the only monocationic N,N-disubstituted 
amide, indicating that too much steric bulk at the terminus resulted in a decrease in antibacterial activity. 
Furthermore, no one particular terminus was found to be superior, as the same terminus on different scaffolds 
gave widely different activities. For example, the monocationic lysine analogue 24 and arginine analogue 30 both 
contain a 4-CF3-benzyl amide terminus and therefore, the arginine analogue 30 was expected to exhibit stronger 
MIC values based upon previous findings; paradoxically, the lysine derivative 24 exhibited stronger MIC values 
(Table 3), indicating that the overall amphipathic conformation of the molecule was likely the dominant 
influencing factor, rather than the individual termini itself. 
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1 20 Biphenyl Lys Bn 8 16 16 8 32 32 
2 21 Biphenyl Lys PhEt 8 8 8 8 32 32 
3 22 Biphenyl Lys Cy 8 16 16 8 16 32 
4 23 Biphenyl Lys CH2Cy 8 8 8 8 16 32 
5 24 Biphenyl Lys 4-CF3-Bn 4 4 4 8 32 32 
6 25 Biphenyl Lys 4-F-PhEt 4 8 8 8 32 64 
7 26 Biphenyl Arg Bn 4 8 8 4 32 64 
8 27 Biphenyl Arg PhEt 2 2 4 4 8 32 
9 28 Biphenyl Arg Cy 4 4 4 4 8 16 
10 29 Biphenyl Arg CH2Cy 4 4 8 8 32 64 
11 30 Biphenyl Arg 4-CF3-Bn 16 16 16 32 128 128 
12 31 Biphenyl Arg 4-F-PhEt 4 4 4 4 64 64 
13 32 Biphenyl Arg 3,5-diF-Bn 8 8 8 16 32 32 
14 33 Biphenyl Arg 3-F-Phenyl 4 8 8 8 32 64 
15 34 Biphenyl Arg 3,5-diMeO-Phenyl 2 2 2 2 16 32 
16 35 Biphenyl Arg Cyclopropyl 4 4 4 4 32 32 
17 36 Biphenyl Arg Cyclopropylmethyl and 
Propyla 
16 32 32 8 64 128 
18 37 Biphenyl Arg Cyclopentenyl 4 4 4 2 16 16 
19 38 (S)-Binaphthyl Arg Bn 4 8 2 8 16 16 
20 39 (S)-Binaphthyl Arg PhEt 8 8 4 16 16 64 
21 Vancomycin - - - 1 1 4 1 0.5 0.5 
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Table 4. Primary screening: antibacterial activities of Series B terminal amide derivatives reported as MIC values (μg/mL). 
 
 







   S. aureus E. faecalis S. pneumoniae C. difficile 













1 42 Bn 8 8 8 8 16 16 
2 43 PhEt 8 8 4 8 16 32 
3 44 Piperidinyla 8 8 8 8 16 32 



































1 49 Biphenyl Lys Arg Bn 4 4 8 4 8 16 
2 50 Biphenyl Lys Arg PhEt 4 4 8 8 16 16 
3 51 Biphenyl Lys Arg Cy 16 16 16 32 64 128 
4 52 Biphenyl Lys Arg CH2Cy 4 4 4 8 16 16 
5 53 Biphenyl Arg Lys Bn 8 8 8 4 32 16 
6 54 Biphenyl Arg Lys PhEt 4 8 8 2 16 16 
7 55 Biphenyl Arg Lys Cy 8 8 8 2 8 16 
8 56 Biphenyl Arg Lys CH2Cy 4 4 4 2 8 16 
9 57 (S)-Binaphthyl Lys Arg PhEt 4 4 4 4 16 16 
10 58 (S)-Binaphthyl Lys Arg CH2Cy 4 4 4 4 16 16 
11 59 (S)-Binaphthyl Arg Lys PhEt 4 4 4 2 16 16 
12 60 (S)-Binaphthyl Arg Lys CH2Cy 4 4 4 2 8 8 
13 Vancomycin - - - - 1 1 4 1 0.5 0.5 
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Table 6. Primary screening: antibacterial activities of Series D non-triazole derivatives reported as MIC values (μg/mL). 




Table 7. Secondary screening: antibacterial activities of Series A derivatives reported as MIC values (μg/mL). 
a N,N-disubstituted amide: two –R groups. 
 
 
   S. aureus E. faecalis S. pneumoniae C. difficile 













1 63 Bn 2 2 2 2 8a 8a 
2 64 PhEt 2 2 4 2 32 32 
3 65 4-F-PhEt >128 >128 >128 >128 >128 64 
4 Vancomycin - 1 1 4 1 0.5 0.5 
 
 




























1 20 Biphenyl Lys Bn 16 32 >32 32 >32 >32 
2 21 Biphenyl Lys PhEt 8 >32 >32 32 >32 >32 
3 22 Biphenyl Lys Cy 8 32 >32 32 >32 >32 
4 23 Biphenyl Lys CH2Cy 8 >32 >32 32 >32 5.6 
5 24 Biphenyl Lys 4-F-PhEt 8 >32 >32 32 >32 >32 
6 25 Biphenyl Lys 4-CF3-Bn 8 >32 >32 16 >32 5.5 
7 26 Biphenyl Arg Bn 8 >32 >32 32 >32 16.8 
8 27 Biphenyl Arg PhEt 8 >32 >32 32 >32 17.9 
9 28 Biphenyl Arg Cy 4 >32 >32 32 >32 19.7 
10 29 Biphenyl Arg CH2Cy 4 >32 >32 >32 >32 16.9 
11 30 Biphenyl Arg 4-F-PhEt 16 >32 >32 >32 >32 >32 
12 31 Biphenyl Arg 4-CF3-Bn 16 >32 >32 >32 >32 19.1 
13 32 Biphenyl Arg 3,5-diF-Bn 16 >32 >32 >32 >32 22.9 
14 33 Biphenyl Arg 3-F-Phenyl 4 >32 >32 >32 >32 >32 
15 34 Biphenyl Arg 3,5-diMeO-
Phenyl 
8 >32 >32 >32 >32 21.6 
16 35 Biphenyl Arg Cyclopropyl 8 >32 >32 >32 >32 12.2 




32 >32 >32 >32 >32 20.0 
18 37b Biphenyl Arg Cyclo-
pentenyl 
8 >32 >32 >32 >32 19.7 
19 38 (S)-Binaphthyl Arg Bn 8 >32 >32 >32 >32 16.5 
20 39 (S)-Binaphthyl Arg PhEt 8 >32 >32 >32 >32 >32 
21 Vancomycin - - - 1 - - - - - 
22 Colistin - - - - 0.25 0.25 0.25 0.125 - 
23 Tamoxifen - - - - - - - - 13.1 
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Table 8. Secondary screening: antibacterial activities of Series B derivatives reported as MIC values (μg/mL). 
a N,N-disubstituted amide. 
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1 42 Bn 4 32 32 32 >32 17.4 
2 43 PhEt 2 32 16 8 >32 15.2 
3 44 Piperidinyl a 2 16 16 8 32 16.8 
4 Vancomycin - 1 - - - - - 
5 Colistin - - 0.25 0.25 0.25 0.125 - 
6 Tamoxifen - - - - - - 13.1 
 
 




























1 49 Biphenyl Lys Arg Bn 4 16 32 16 8 17.1 
2 50 Biphenyl Lys Arg PhEt 2 8 16 8 8 16.4 
3 51 Biphenyl Lys Arg Cy 4 16 16 8 8 19.8 
4 52 Biphenyl Lys Arg CH2Cy 2 32 16 8 8 19.1 
5 53 Biphenyl Arg Lys Bn 8 16 32 32 >32 >32 
6 54 Biphenyl Arg Lys PhEt 4 16 16 32 16 >32 
7 55 Biphenyl Arg Lys Cy 4 8 16 16 16 >32 
8 56 Biphenyl Arg Lys CH2Cy 8 16 16 16 16 >32 
9 57 (S)-Binaphthyl Lys Arg PhEt 2 16 >32 8 >32 >32 
10 58 (S)-Binaphthyl Lys Arg CH2Cy 2 32 >32 8 >32 16.6 
11 59 (S)-Binaphthyl Arg Lys PhEt 4 32 >32 32 >32 >32 
12 60 (S)-Binaphthyl Arg Lys CH2Cy 32 32 >32 32 >32 >32 
13 Vancomycin - - - - 1 - - - - - 
14 Colistin - - - - - 0.25 0.25 0.25 0.125 - 




Table 10. Secondary screening: antibacterial activities of Series D non-triazole derivatives, reported as MIC values (μg/mL). 
 
2.3. Haemolysis Assay 
Selected peptidomimetic derivatives were subjected to a haemolysis assay with sheep erythrocytes at 
concentrations of 5 µg/mL and 50 µg/mL; UltraPure H2O was utilized as a positive control (i.e. set as 100% 
haemolysis) and the results are displayed in Table 11. 
 





5 µg/mL 50 µg/mL 
23 0.0% 98.0% 
28 1.4% 81.8% 
39 0.1% 55.2% 
50 1.4% 12.6% 
56 1.6% 33.7% 
57 1.5% 75.2% 
60 1.8% 71.5% 
63 0.3% 100.5% 
 
When tested at the lower testing concentration of 5 µg/mL, the peptidomimetic compounds exhibited minimal 
haemolysis (i.e. <2%). The tested monocationic compounds 23, 28, 39, and 63 displayed strong haemolytic 
activity (>50%) at the higher testing concentration, as expected due to their unoptimized cationic/hydrophobic 
ratio [28]. Gratifyingly, the biphenyl bis-triazole derivatives 50 and 56 exhibited substantially reduced haemolysis, 
with compound 50 displaying <13% haemolysis at the higher testing concentration. The corresponding (S)-
binaphthyl analogues 57 and 60 exhibited higher levels of haemolysis relative to their biphenyl counterparts 50 
and 56, respectively. These findings were expected, as it has previously been shown that an increase in the ratio 
of cationic-to-hydrophobic substituents results in an increase in selectivity for the anionic bacterial membrane 
over the zwitterionic mammalian membrane [28].   Interestingly, the obtained cytotoxicity (CC50) values (Tables 
7–10) did not always correlate with the haemolysis data; compound 56 was not cytotoxic at ≤32 µg/mL, whereas 
 


























1 63 Bn 4 >32 >32 >32 >32 >32 
2 64 PhEt 4 >32 >32 >32 >32 >32 
3 65 4-F-PhEt 4 >32 >32 >32 >32 >32 
4 Vancomycin - 1 - - - - - 
5 Colistin - - 0.25 0.25 0.25 0.125 - 
6 Tamoxifen - - - - - - 13.1 
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compound 50 exhibited a CC50 of 16.4 µg/mL. The opposite pattern was observed amongst the haemolysis data, 
wherein compound 56 was found to be approximately 2× more haemolytic than compound 50.  
 
2.4. Comparative solubility assay 
Initial in vivo murine studies revealed poor solubility in 10% DMSO/H2O for some of the (S)-binaphthyl 
analogues, so a comparative solubility assay was developed to ascertain the relative solubilities of the synthesized 
peptidomimetic compounds. 
 
Fig. 5. Prototypical biarylpeptidomimetic compound 66. 
The prototypical biarylpeptidomimetic 66 [33] (Fig. 5) was used as the standard for solubility comparison and all 
other compounds were compared to this compound. The compound of interest (5.0 mg) was fully dissolved in 
DMSO (50 μL) and then H2O aliquots (5 μL) were added with adequate manual agitation in between additions. 
Addition of H2O was continued until a persistent turbidity and cloudiness was apparent that did not fade after 
agitation. Compound 66 precipitated after the addition of 15 μL H2O; compounds that required twice as much 
water were effectively two times more soluble than compound 66 (i.e. solubility ratio = 2). The solubility assay 
was performed on a varied sample of the synthesized compounds to ascertain which structural elements were 
beneficial for solubility (Table 12).  
Table 12. Comparative solubility assay data and CLogP values for selected compounds.  








66 15 1 7.47 
1 45 3 4.6 
23 >200NP >13.3NP 5.81 
28 30 2 3.77 
51 30 2 4.07 
56 55 3.67 4.60 
60 15 1 6.94 
63 15 1 5.82 
67 45 3 5.76 
68 15 1 6.50 
69 60 4 4.07 
NP = No precipitation observed. 
Comparison of the CLogP value and a compound’s measured solubility revealed no definitive correlation between 
the two factors. As expected, the biphenyl derivatives were much more soluble than their corresponding (S)-
binaphthyl analogues – for example, the biphenyl analogue 56 was almost four times more soluble than its (S)-
binaphthyl counterpart 60 (Table 12). Compounds that contained a single lysine amino acid side-chain (e.g. 
compound 23) were found to be substantially more soluble than the corresponding arginine containing analogues 
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(e.g. compound 28); an alternative precipitation procedure (General Procedure D) was required for synthesis of 
the mono-lysine derivatives due to their increased solubility in Et2O. 
Notably, no one particular orientation of amino acid residues amongst the dicationic derivatives was found to give 
rise to increased solubility, as the solubility was likely reliant on multiple complex factors (e.g. scaffold shape, 
hydrogen bonding, solvent effects and overall conformation).  
The solubility ratio data allowed for the selection of compounds for the in vivo mouse model of CDI with varying 
solubilities so that the effect of solubility on the drug’s administration, efficacy and pharmacokinetic parameters 
could be observed. Compounds required a solubility ratio of three or greater to prevent immediate precipitation 
and flocculation of the compound after dilution of the DMSO stock solution with H2O. 
 
2.5. In vivo murine model for treatment of CDI 
Compounds from this study and previous studies [28-29] were selected for use in a murine in vivo C. 
difficile infection treatment model [45] based upon their MIC values against C. difficile and varying solubility 
parameters. An initial study with two compounds (Fig. 6) was performed followed by a second study with four 
compounds (Fig. 7).   
 
 
Fig. 6. Compounds 67 [28] and 68 [29] utilized in the initial in vivo CDI model; MIC values against C. difficile are displayed 
in µg/mL. The solubility ratio (SR) of each compound relative to compound 66 is displayed with a qualitative observation of 
the solubilisation in 10% DMSO. Haemolysis = Percent (%) haemolysis at 50 µg/mL. 
 
 
Fig. 7. Selected compounds 28, 63, 69 [28] and 1 [28] utilized in the secondary in vivo CDI model; MIC values against C. 
difficile are displayed in µg/mL. The solubility ratio (SR) of each compound relative to compound 66 is displayed with a 
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qualitative observation of the solubilisation in 10% DMSO. Haemolysis = Percent (%) haemolysis at 50 µg/mL. *Compound 
63 displayed an MIC value of 2 µg/mL against C. difficile M7404 at the Monash University laboratory. 
 
Cohorts of mice (n = 4–5) were pre-treated with an antibiotic cocktail to induce susceptibility to bacterial infection 
followed by infection with C. difficile (ribotype 027 – strain M7404 [46]) spores via oral gavage. Each cohort was 
then administered either a test compound, vancomycin or a 10% DMSO control by oral gavage every 12 h starting 
from six hours after the initial infection. The mice were then monitored for weight loss, survival and physiological 
parameters for up to four days. Tables defining the physiological parameter scoring rubrics can be found in the 
supplementary information (Tables S1–S3). 
 
The initial in vivo murine CDI model was performed on compounds 67 and 68 with vancomycin and 10% DMSO 
as positive and negative controls, respectively (Fig. 8). At twenty-four hours post-infection, compound 67 
appeared to be protecting the mice from disease; these mice had the least diarrhoea (as shown by the fecal 
consistency score and cage appearance score) and their appearance was significantly better than the 10% DMSO 
control mice (Fig. 8). Furthermore, these mice showed a 50% survival rate (2/4 mice) compared to 0% survival 
in the 10% DMSO group, although this was not statistically significant due to the small sample size (Fig. 8a). 
These results clearly show that compound 67 exhibited a notable positive effect in the treatment of CDI. 
Compound 68 exhibited poor solubility during the in vivo trial, as the compound was found to precipitate during 
preparation in a 10% DMSO solution; these results prompted a review of the solubility parameters before further 
in vivo studies were conducted. 
 
A secondary in vivo murine CDI model was performed with compounds 28, 63, 69 and 1; these four compounds 
were selected due their potent in vitro activity against C. difficile in conjunction with their varying solubility 
profiles and structural motifs. At twenty-four hours post-infection, compound 28 appeared to be protecting the 
mice from disease; these mice had the least amount of weight loss at day 1 (not statistically significant) and they 
had the least amount of diarrhoea, as shown by the fecal consistency score and cage appearance score (Fig. 9). 
Furthermore, these mice physically looked the healthiest with 4/5 mice surviving until day 2, compared with only 
2/5 mice from the 10% DMSO control cage surviving until day 2. Notably, compound 63 seemed to make the 
disease worse, as all 5 mice in this cohort were euthanized at 1 day post-infection and were worse than the 10% 
DMSO control mice in appearance (statistically significant), diarrhoea and weight loss (Fig. 9). Unfortunately, 
none of the compounds were able to fully protect the mice and all mice succumbed to infection by day 2 post-
infection. Compound 28 performed significantly better than the DMSO control, providing some evidence of in 
vivo efficacy.  
 
While the results from the in vivo murine CDI models were promising, the observed efficacy did not correlate 
with the in vitro MIC activities. For example, compound 28 exhibited the weakest MIC activity against C. difficile 
amongst the secondary in vivo trial derivatives; yet this compound performed better than the more potent 
analogues 63, 69 and 1. The non-triazole compound 63 exhibited the strongest in vitro MIC activity against C. 
difficile, yet it performed the worst out of the tested compounds. Unexpectedly, the more potent, more soluble and 
less haemolytic dicationic compounds 1 and 69 failed to perform as well as compound 28 (Fig. 9); there were no 
apparent correlations between a compound’s MIC value, solubility, haemolysis and in vivo efficacy against CDI. 
 
Overall, both compounds 67 and 28 displayed significant evidence of in vivo efficacy in the treatment of CDI, 

































































































































































































Fig. 8. Initial in vivo murine CDI model. C57BL/6J mice (n = 4–5 per group) were infected with 105 spores of C. difficile strain M7404 prior to treatment with DMSO, compound 67, compound 
68 or vancomycin and monitored daily for survival (a) and weight loss (b). Fecal spore load at 1 day post-infection was determined by plating (c). Data are presented as CFU/gram feces, with 
each point representing a single mouse. The dotted line represents the limit of detection of the assay. Mouse cages were scored on day 1 post-infection for appearance (d) and mice were individually 
assessed for fecal consistency (e) and physiological appearance (f). Data represent the mean ±S.E.M. and statistical significance was assessed using a log-rank (Mantel-Cox) test or one-way 
































































































































































































Fig. 9. Secondary in vivo murine model of CDI. C57BL/6J mice (n = 5 per group) were infected with 105 spores of C. difficile strain M7404 prior to treatment with DMSO, compound 28, 
compound 69, compound 1 or compound 63 and monitored daily for survival (a) and weight loss (b). Fecal spore load at 1 day post-infection was determined by plating (c). Data are presented as 
CFU/gram feces, with each point representing a single mouse. Mouse cages were scored on day 1 post-infection for appearance (d) and mice were individually assessed for fecal consistency (e) 
and physiological appearance (f). Data represent the mean ±S.E.M. and statistical significance was assessed using a log-rank (Mantel-Cox) test or one-way ANOVA with a post-hoc Tukey’s 







2.6. Pharmacokinetics assay 
 Since CDI chemotherapeutics are required to stay in the GI tract to treat the infection, systemic absorption 
of the target antibiotic drug is not desirable. Therefore, pharmacokinetic analysis was performed on the blood and 
feces of mice that were infected with C. difficile and treated with lead compound 67 in the initial murine model 
of CDI (Section 2.5). 
To ascertain the presence of compound 67 in the blood and feces, an extraction/analysis procedure employing 
low-resolution mass spectrometry (LRMS) was developed and utilized (Section 4.6). The mouse blood was diluted 
with PBS and then extracted with CH2Cl2 (× 2); the feces was extracted with CH2Cl2 (× 1). Concentration of the 
extracts and LRMS analysis of the residues revealed the presence of the drug (i.e. the doubly-protonated molecular 
ion, m/2 = 421 = [M + 2H]2+) in the feces; whereas no drug could be found in the blood. To ensure the procedure 
was viable, mouse blood from an untreated cohort was doped to achieve a final concentration of compound 67 
equivalent to an average 25 g mouse absorbing 1% of the total dose into its bloodstream – the drug was readily 
detected in the doped mouse blood, verifying the validity of the extraction protocol. 
These findings confirm that compound 67 was not absorbed systemically into the bloodstream by the mice; 
following oral administration, the drug clearly stayed in the GI tract (i.e. feces).  
2.7. Cytoplasmic membrane depolarization assay 
A cytoplasmic membrane depolarization assay with 3,3ʹ-dipropylthiadicarbocyanine (diSC3(5)) 
fluorescent dye [37, 47] was performed on compounds 28 and 50 against S. aureus (ATCC 29213) and E. coli 
(NCTC 10418) as described previously [28] to investigate the molecular mode of action. Compounds 28 and 50 
were observed to strongly disrupt the electrochemical gradient of S. aureus at a testing concentration of 32 µg/mL 
(i.e. 8 × MIC) (Fig. 10, top). DMSO (20% aq.) was utilized as a positive control, resulting in a significant increase 
in observed fluorescence for both S. aureus and E. coli (Fig. 10). UltraPure H2O and vancomycin (for S. aureus 
only) were employed as negative controls and they failed to generate any increase in fluorescence. Furthermore, 
both compounds 28 and 50 were shown to depolarize the cytoplasmic membrane of E. coli when tested at 64 
µg/mL (i.e. ≤8 × MIC), as shown by a large increase in the observed fluorescence (Fig. 10, bottom); the 
compounds elicited substantially stronger fluorescence than the positive control, colistin.  
These results further confirm the previously elucidated membrane disruption mechanism inherent to these 

































Fig. 10 – Cytoplasmic membrane depolarization assays for compounds 28 and 50 tested at 32 µg/mL against S. aureus (top) 
and 64 µg/mL against E. coli (bottom). Vancomycin tested at 8 µg/mL (8 × MIC) and colistin tested at 4 µg/mL (32 × MIC). 
 
2.8. Cytoplasmic membrane permeabilization assay 
A cytoplasmic membrane permeabilization assay with propidium iodide [47-48] was conducted with 
compounds 28 and 50 against S. aureus and E. coli as previously described [28]. Compounds 28 and 50 exhibited 
a strong increase in fluorescence (>500%) in the assay against S. aureus, indicating permeabilization of the cellular 
membrane (Fig. 11, top). The negative controls vancomycin and UltraPure H2O failed to give an increase in 
fluorescence, as expected. As observed previously [28], the monocationic derivative 28 displayed a faster and 
stronger increase in fluorescence compared to the dicationic compound 50; the monocationic analogue 28 took 
approximately 10 min to reach maximal fluorescence while the dicationic derivative 50 took approximately 40 
min (Fig. 11, top). These results further confirm that the smaller, monocationic peptidomimetics likely 
permeabilize the cytoplasmic membrane of S. aureus more rapidly and effectively than the larger, dicationic 
derivatives. Permeabilization of the cytoplasmic membrane of E. coli by the peptidomimetics 28 and 50 was 
comparable to the permeabilization seen with the positive control, colistin (as indicated by the observed 
fluorescence) – yet this increase in fluorescence was notably reduced and slower (Fig. 11, bottom) relative to the 
fluorescence increase seen with S. aureus. This reduction in membrane permeabilization efficacy against E. coli 
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Fig. 11 – Cytoplasmic membrane permeabilization assays for compounds 28 and 50 tested at 32 µg/mL against S. aureus 
(top) and E. coli (bottom). Vancomycin was tested at 8 µg/mL (8 × MIC) and colistin was tested at 4 µg/mL (32 × MIC). 
 
3. Conclusion 
A simplified, modular synthetic pathway was employed to furnish thirty-eight novel cationic biaryl 1,2,3-
triazolyl amphiphilic peptidomimetics. Nine variable scaffolds were developed and subsequently derivatized into 
twenty monocationic amide analogues (A), three dicationic amide analogues (B), twelve dicationic bis-triazole 
analogues (C) and three non-triazole analogues (D).  The late-stage divergent methodology utilized the robust 
CuAAC and peptide coupling reactions to give facile synthetic access to the small library of antibacterial 
derivatives. Furthermore, the optimized synthetic pathway allowed access to the antibacterial scaffolds with 
substantially reduced synthetic labour. The synthesized compounds were found to exhibit potent antibacterial 
efficacy in vitro against a broad range of pathogenic Gram-positive and Gram-negative bacteria. 
Compounds 28 and 67 exhibited significant evidence of in vivo efficacy in the murine CDI treatment models; 
further investigation into the structural and biological parameters affecting the in vivo efficacy of these 
antibacterial peptidomimetics is warranted, as the observed in vitro efficacy does not translate directly into in vivo 
efficacy. Preliminary pharmacokinetics assay results indicate that compound 67 is not absorbed systemically and 
that the compound remains in the GI tract following oral administration. Haemolytic testing revealed a correlation 
between an increased hydrophobic/cationic ratio and increased haemolytic activity; notably, compound 50 was 
found to exhibit substantially reduced haemolysis (<13%) relative to the majority of the tested analogues.  
Membrane disruption assay results strongly suggest a membrane-active mode of action for the amphiphilic 
peptidomimetics. A comparative solubility assay was developed that allowed for the identification of structural 
moieties that influenced the aqueous solubility of the synthesized peptidomimetics.  
Identification of the parameters influencing the in vivo efficacy (e.g. solubility and membrane 
selectivity/haemolytic activity) against C. difficile will allow for the rational design and development of future 
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4. Experimental section 
4.1. General information 
Synthesis 
Unless stated otherwise, all solvents and chemicals were laboratory or reagent grade and were purchased 
from commercial sources. All chemicals were used as received. Water was purified via Millipore filtration prior 
to use. HOBt and propargyl bromide were purchased with added stabilizers (10% w/w H2O and 20% w/w toluene, 
respectively); therefore, the quantities required for reactions were adjusted accordingly and are reflected in the 
reagent masses reported in the experimental (whereas the reported mmol quantities reflect the true quantity of 
chemical). All reactions were conducted under normal atmosphere and cold reaction temperatures were obtained 
by an ice bath (0 ºC) or ice/salt bath (–10 ºC). Heating of reactions was performed with a paraffin oil bath. Small 
quantities of liquid reagents were measured and added to reactions via syringe or autopipette. Unless otherwise 
noted, all filtrations were conducted as vacuum filtration through a sintered glass funnel (medium porosity). 
Vacuum filtration was achieved with the aid of a water aspirator. Solvent removal via concentration was 
performed on a rotary evaporator under reduced pressure. All solvent mixtures are expressed in terms of volume 
ratio (i.e. v/v). Thin layer chromatography (TLC) was performed on aluminium-backed SiO2 gel plates (F254 grade 
- 0.20 mm thickness). Visualization was achieved with UV light, ninhydrin stain or cerium ammonium molybdate 
stain. Flash chromatography was performed on SiO2 gel 60 with positive air pressure. All synthesized compounds 
were dried under high vacuum (< 1 mbar) before determination of chemical yields and spectroscopic 
characterization. 
Characterization and analysis 
1H NMR spectra were recorded on a Bruker Avance 400 (400 MHz), a Varian VNMRS PS54 500 (500 
MHz), a Varian Inova 500 (500 MHz) or a Varian Mercury 300 (300 MHz) NMR spectrometer. Chemical shifts 
are reported in ppm and were measured relative to the internal standard. Samples were dissolved in CDCl3 (with 
TMS as the internal standard – 0.00 ppm), CD3OD (solvent resonance as internal standard – 3.31 ppm) or DMSO-
d6 (solvent resonance as internal standard – 2.50 ppm). The 1H NMR data is reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dt = doublet of triplets, m = multiplet, br = broad), 
coupling constants (Hz) and integration. 13C NMR spectra were recorded on a Bruker Avance 400 (101 MHz), a 
Varian VNMRS PS54 500 (126 MHz), a Varian Inova 500 (126 MHz) or a Varian Mercury 300 (75 MHz) NMR 
spectrometer with complete 1H decoupling. Chemical shifts are reported in ppm and were measured relative to 
the internal standard. Samples were dissolved in CDCl3 (solvent resonance as the internal standard – 77.16 ppm), 
CD3OD (solvent resonance as the internal standard – 49.20 ppm) or DMSO-d6 (solvent resonance as internal 
standard – 39.50 ppm). 1H and 13C NMR assignments were confirmed by analysis of NMR APT, gCOSY, gHSQC, 
gHMBC and/or zTOCSY experiments. Ambiguous degenerate carbon resonances are marked with a single 
asterisk * (representing two carbons) or a double asterisk ** (representing three or more carbons) for clarity. 
Carbon resonances that required 2-D NMR analysis for assignment (i.e. not observed via 1-D 13C NMR analysis) 
are marked with the label “observed by gHMBC” or “observed by gHSQC”. NMR spectra were processed, 
analysed and prepared with MestReNova (version 6.0) NMR software. Low-resolution mass spectra (LRMS) 
were obtained via electrospray ionization (ESI) on a Shimadzu LC-2010 mass spectrometer. LRMS data was 
recorded as the ion mass/charge ratio (m/z) with the corresponding relative abundance as a percentage. High-
resolution mass spectrometry (HRMS) was performed on a Waters Quadrupole-Time of Flight (QTOF) Xevo 
spectrometer via ESI and with Leucine-Enkephalin as an internal standard. All mass spectrometry samples were 
dissolved in high-performance liquid chromatography (HPLC) grade MeOH (containing <1% formic acid for 
ionization). Optical rotations were measured on a Jasco P-2000 polarimeter with a 10 cm path length; rotation 
values (α) are expressed in units of “deg cm3 g-1 dm-1” with concentration (c) expressed in units of “g/100 mL”. 
Solid-state infrared spectroscopy was performed on a Shimadzu IRAffinity-1 FTIR spectrometer in combination 
with a MIRacle 10 Single Reflection Attenuated Total Reflectance accessory outfitted with a 1.5 mm round 
diamond crystal. IR peaks are reported as the wavenumber (ν̄max in cm-1) of the maximum absorption. Analytical 
HPLC was performed on a Phenomenex Synergi 4u Fusion-Reverse Phase 80Å column (φ = 4.6 × 150 mm) with 




Notes and other considerations 
Known reagents that were not available commercially were prepared according to the literature 
procedures cited within the supplementary information. The experimental section contains a representative 
synthesis of final compound 28 utilizing the general synthetic procedures outlined in Section 4.2; the synthetic 
and characterization data for all other compounds can be found within the supplementary information. Synthesized 
compounds that contain the (S)-isopentyloxybinaphthalene fragment and some chiral compounds that contain the 
isopentyloxybiphenyl fragment exhibited a pair of diastereotopic methyl (-CH3) groups on the terminus of the 
isopentyl substituent; these carbons are consistently referred to as C4 and C5. Importantly, these two carbons 
(and associated protons) would sometimes exhibit distinct NMR chemical shifts due to the chiral environment 
imposed by the amino acid residue(s) (for all derivatives) and/or the adjacent (S)-binaphthyl moiety (for (S)-
binaphthyl derivatives only). 
4.2. General synthetic procedures 
General Procedure A: Copper catalyzed azide-alkyne cycloaddition  
 To a reaction vessel charged with the azide (1.0 eq), alkyne (2.0 – 3.0 eq), Cu(OAc)2∙H2O (0.2 eq), and 
sodium ascorbate (0.4 eq) was added t-BuOH (20 mL/mmol azide) and H2O (5 mL/mmol azide). The mixture was 
initially sonicated for < 1 min followed by vigorous stirring at rt (unless noted otherwise) for the specified time. 
The reaction mixture was diluted with EtOAc (20 mL for reactions that contained ≤ 1.0 mmol azide or 20 
mL/mmol azide for larger scale reactions) and washed with an equivalent volume of saturated aqueous NH4Cl 
solution (e.g. 20 mL). The organic phase was dried (MgSO4), filtered, concentrated and the residue was subjected 
to flash chromatography over SiO2 gel to afford the desired 1,4-disubstituted-1,2,3-triazole product.  
General Procedure B: Amide coupling 
The amine (1.0 eq), carboxylic acid (1.0 – 1.2 eq), EDCI (1.2 eq) and HOBt (1.1 eq) were combined in 
an acetonitrile solution (10 mL/mmol amine) and stirred at rt for the specified time. The solvent was removed (not 
required for ≤ 5.0 mL acetonitrile) and the residue was dissolved in EtOAc (25 mL for reactions that contained ≤ 
1.0 mmol amine or 25 mL/mmol amine for larger scale reactions). The organic solution was washed successively 
with aqueous HCl (1.0 M – 2 × 25 mL), saturated aqueous NaHCO3 (3 × 25 mL) and brine (1 × 25 mL). The 
EtOAc solution was dried (MgSO4), filtered and concentrated. If necessary, the residue was subjected to further 
purification via flash chromatography over SiO2 gel to furnish the targeted amide product. 
General Procedure C: Amine deprotection (N-Boc and/or N-Pbf removal) 
The N-protected amine (1.0 eq) was dissolved in a CH2Cl2 (30 mL/mmol substrate) with magnetic 
stirring. If the substrate molecule contained an N-Pbf moiety then H2O (20.0 eq) was also added to the solution. 
TFA (30.0 mL/mmol substrate) was then added and the reaction mixture was stirred at rt overnight (> 16 h) 
followed by removal of the solvent. The residue was dissolved in CH2Cl2 (30 mL/mmol substrate), an excess 
amount of anhydrous HCl (2.0 M in Et2O, 15 mL/mmol substrate, 30.0 eq) was added and the solvent was then 
removed. The resulting residue was dissolved in a minimal volume of CH2Cl2 (or MeOH) and excess Et2O (25 
mL for ≤ 0.1 mmol substrate) was added to precipitate the hydrochloride salt of the amine. The solvent was 
removed by filtration and the product (both in the filter funnel and in the flask) was triturated with Et2O (3 × 20 
mL). The product was collected by dissolution in MeOH; concentration followed by drying in vacuo gave the 
final mono- or di-hydrochloride salt as a thin, translucent film that was routinely scratched with a spatula into a 
fine hygroscopic powder or amorphous gum.  
General Procedure D: Modified amine deprotection (N-Boc removal) 
For the biphenyl monocationic lysine derivatives (38–40), General Procedure C was followed with the following 
modifications: Et2O (instead of CH2Cl2 or MeOH) was utilized to dissolve the residue for final precipitation and 






4.3. Representative synthesis of compound 28 from precursor building blocks 12 and 15 
(R)-2-(4-(((2'-(Isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-5-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentanoic acid (17) 
Following General Procedure A, azide 15 (1.20 g, 2.65 mmol), alkyne 12 (1.56 g, 5.30 mmol), 
Cu(OAc)2∙H2O (106 mg, 0.53 mmol) and sodium ascorbate (210 mg, 1.06 mmol) were stirred in t-BuOH (53 mL) 
and H2O (13.3 mL) for 18 h to give the product triazole 17 (1.63 g, 82%) as a translucent tan gum after flash 
chromatography over SiO2 gel (EtOAc/P.S. – 10:90  MeOH/CH2Cl2 – 10:90). TLC (MeOH/CH2Cl2 – 10:90): 




 −28.1 (c 1.03, MeOH); 1H NMR (400 MHz, DMSO) δ 7.84 (s, 
1H, H5'), 7.60 (br s, 1H), 7.33 – 7.18 (m, 3H), 7.18 – 7.10 (m, 2H), 7.01 – 6.94 (m, 2H), 6.88 (t, J = 7.3 Hz, 1H), 
6.80 (br s, 2H), 5.06 (s, 2H), 4.91 (br s, 1H), 3.93 – 3.81 (m, 2H), 3.07 – 2.96 (m, 2H), 2.94 (s, 2H), 2.47 (s, 3H), 
2.41 (s, 3H), 2.22 – 2.07 (m, 1H), 1.99 (s, 3H), 1.91 – 1.77 (m, 1H), 1.54 (td, J = 13.2, 6.6 Hz, 1H), 1.45 – 1.33 
(m, 8H), 1.23 (br s, 1H), 1.07 (br s, 1H), 0.76 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, DMSO) δ 157.4, 156.32, 
156.27, 156.1, 155.7, 142.6, 137.2, 134.3, 131.4, 131.2, 131.1, 128.5, 128.4, 127.9, 127.4, 124.3, 123.1, 120.4, 
119.9, 116.2, 113.0, 112.2, 86.2, 66.2, 64.9, 62.2, 42.5, 39.5 (observed by gHSQC), 37.5, 30.2, 28.3, 25.9, 24.5, 
22.4*, 18.9, 17.6, 12.3; IR (neat) ν̄max 3327, 2946, 2873, 2831, 2363, 2167, 2027, 1617, 1559, 1506, 1442, 1405, 
1238, 1108, 1023, 804, 751, 668 cm-1; MS (ESI +ve) m/z 747 ([M + H]+, 100%), MS (ESI −ve) m/z 745 ([M − 
H]−, 100%); HRMS (ESI +ve TOF) calcd for C39H51N6O7S 747.3540, found 747.3572 ([M + H]+). 
 
(R)-N-Cyclohexyl-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-
yl)pentanamide hydrochloride (28) 
Following General Procedure B, acid 17 (50 mg, 0.07 mmol), cyclohexylamine (8 mg, 0.08 mmol), 
EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol) were stirred in acetonitrile (0.7 mL) for 21 h to give 
the intermediate amide as a translucent tan gum. Following General Procedure C, the amide was dissolved in 
CH2Cl2 (2.0 mL) and treated with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with 
ethereal HCl to give the amine salt 28 (39 mg, 95% over two steps) as a light tan powder that rapidly transitioned 




 +15.9 (c 0.83, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H), 7.34 – 7.24 (m, 2H), 
7.23 – 7.09 (m, 3H), 7.05 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.24 (t, J = 7.7 Hz, 1H), 5.14 – 5.05 (m, 2H), 
3.96 – 3.85 (m, 2H), 3.68 – 3.57 (m, 1H), 3.18 (t, J = 7.0 Hz, 2H), 2.22 – 2.00 (m, 2H), 1.92 – 1.12 (m, 15H), 0.77 
(d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 168.7, 158.8, 158.2, 157.5, 146.2, 132.7, 132.5, 130.7*, 
129.9, 129.7, 124.0, 122.5, 121.5, 114.7, 113.8, 68.2, 64.8, 64.1, 50.4, 41.9, 39.4, 33.7, 33.6, 31.1, 26.7, 26.4, 
26.3, 26.20, 26.16, 23.1*; IR (neat) ν̄max 3329, 3185, 3067, 2953, 2929, 2868, 2364, 2323, 1684, 1669, 1653, 1617, 
1559, 1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1213, 1123, 1108, 1088, 1040, 1003, 941, 855, 802, 749, 
668 cm-1; MS (ESI +ve) m/z 576 ([M + H]+, 100%), 598 ([M + Na]+, 19%); HRMS (ESI +ve TOF) calcd for 
C32H46N7O3 576.3662, found 576.3688 ([M + H]+). 
 
4.4. Microbiology assays 
 
4.4.1. Primary screening (Gram-positive bacteria)  
Primary MIC assays were performed as described by the Clinical and Laboratory Standards Institute for 
aerobic [49] and anaerobic [50] bacteria. S. aureus strains ATCC 29213 and NCTC 10442 (MRSA) and E. faecalis 
(ATCC 29212) were tested in Mueller Hinton broth (MHB) and incubation was performed in ambient air at 35 °C 
for 24 h. S. pneumoniae (ATCC 49619) was cultivated in MHB with 2.5% lysed horse blood and incubated with 
5% CO2 at 35 °C for 24 h. MIC studies for C. difficile strains ATCC 700057 and NSW132 (RT027) were 
conducted in pre-reduced (2-4 h) Brucella broth supplemented with haemin and vitamin K and incubation was 
performed anaerobically at 35 °C in a Don Whitley Scientific anaerobic chamber (A35) for 48 h. Each compound 
was dissolved in DMSO at 5 mg/mL and then diluted to 512 μg/mL with sterile, distilled water. The compounds 
were then serially diluted in 100 μL volumes of sterile, distilled water in a 96-well microtitre tray. Each test 
organism in double strength broth (100 μL) was then added to each well and incubated as described above. Final 
testing concentrations of the compounds ranged from 0.25 μg/mL to 128 μg/mL. Vancomycin and a control well 
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(i.e. no antibacterial compound present) were included in the assays. A DMSO control (5% v/v) was also tested 
to ensure that the solvent did not inhibit bacterial growth. The assay was performed in triplicate for each 
organism/compound combination and the modal MIC values were recorded. The MIC was determined visually 
as the lowest concentration that inhibited bacterial growth. Concentrations of ≤5% DMSO were not inhibitory to 
growth. MIC values for vancomycin were within acceptable QC ranges [51]. 
 
4.4.2. Secondary screening (MRSA and Gram-negative bacteria) and cytotoxicity assay – performed by the 
Community for Open Antimicrobial Drug Discovery (CO-ADD) 
 Samples were provided to CO-ADD [34] for antimicrobial screening by whole cell growth inhibition 
assays. The inhibition of growth was measured against five bacteria: E. coli (ATCC 25922), K. pneumoniae 
(ATCC 700603), A. baumannii (ATCC 19606), P. aeruginosa (ATCC 27853) and S. aureus (ATCC 43300). In 
addition to the MIC assay, compounds were screened for cytotoxicity against a human embryonic kidney cell line 
(HEK293) by determining their CC50 value. Samples were prepared in DMSO to a final testing concentration of 
32 μg/mL and serially diluted 1:2 fold for 8 times. Each sample concentration was prepared in 384-well plates; 
non-binding surface (NBS) plates (Corning 3640) for each bacterial strain and black plates (Corning 3712/3764) 
for mammalian cell types, all in duplicate (n = 2) and keeping the final DMSO concentration to a maximum of 
0.5%. All the sample preparation was done using liquid handling robots.  
Bacterial Inhibition – MIC Assay 
All bacteria were cultured in Cation-adjusted MHB at 37 °C overnight. A sample of each culture was then diluted 
40-fold in fresh broth and incubated at 37 °C for 1 – 3.5 h. The resultant mid-log phase cultures were diluted 
(CFU/mL measured by OD600), then added to each well of the compound-containing plates, giving a cell density 
of 5 × 105 CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 37 °C for 18 h without 
shaking. Inhibition of bacterial growth was determined by measuring absorbance at 600 nm (OD600), using a Tecan 
M1000 Pro monochromator plate reader. The percentage of growth inhibition was calculated for each well, using 
the negative control (media only) and positive control (bacteria without inhibitors) on the same plate as references. 
The MIC was determined as the lowest concentration at which growth was fully inhibited, defined by an inhibition 
≥80%. Colistin and vancomycin were used as positive bacterial inhibitor standards for Gram-negative and Gram-
positive bacteria, respectively. Each antibiotic standard was provided in four concentrations, with two above and 
two below its MIC value, and plated into the first eight wells of column 23 of the 384-well NBS plates. 
Cytotoxicity Assay 
HEK293 cells were counted manually in a Neubauer haemocytometer and then plated in the 384-well plates 
containing the compounds to give a density of 5000 cells/well in a final volume of 50 μL. Dulbecco’s modified 
eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) was used as a growth media and the 
cells were incubated together with the compounds for 20 h at 37 °C in 5% CO2. Cytotoxicity (cell viability) was 
measured by fluorescence (ex: 560/10 nm, em: 590/10 nm), after addition of 5 μL of 25 μg/mL resazurin (2.3 
μg/mL final concentration) and after incubation for further 3 h at 37 °C in 5% CO2. The fluorescence intensity 
was measured using a Tecan M1000 Pro monochromator plate reader, using automatic gain calculation. CC50 
(concentration at 50% cytotoxicity) values were calculated by curve-fitting the inhibition values vs. 
log(concentration) using a sigmoidal dose-response function, with variable fitting values for bottom, top and 
slope. Tamoxifen was utilized as a positive cytotoxicity standard; it was used in eight concentrations in two-fold 
serial dilutions with 50 μg/mL as the highest concentration tested. 
 
4.4.3. Haemolysis assay 
The haemolytic activity of the synthesized compounds was determined by lysis of sheep erythrocytes. 
Briefly, 500 μL volumes of each compound in phosphate buffer solution (PBS) were mixed with 480 μL PBS and 
20 μL washed sheep erythrocytes (100%) in microcentrifuge tubes; this produced a final erythrocyte concentration 
of 2%. Compounds were tested at both 5 μg/mL and 50 μg/mL. A positive control (980 μL water and 20 μL 
erythrocytes) and a negative control (980 μL PBS and 20 μL erythrocytes) were also included in the assay. The 
centrifuge tubes were incubated on a rocker at 37 °C for 2 h and then centrifuged at 12,000 rpm for 5 min; 100 
µL volumes of the supernatant fluid were transferred to a 96-well microtitre tray and the optical density of the 
samples was observed at 540 nm. The value for the negative control was subtracted from the haemolysis values 
30 
 
and then the resulting quantities were expressed as a percentage of the positive control (which was defined as 
100% haemolysis). The haemolysis assay was repeated in triplicate for all compounds and the mean values were 
reported. 
4.4.4. Cytoplasmic membrane depolarization assay 
An inoculum containing 1.5 McFarland standard of mid-log cells (S. aureus ATCC 29213 or E. coli 
NCTC 10418) was suspended in either phosphate buffered saline (PBS – for S. aureus) or a 5 mM HEPES solution 
containing 20 mM glucose adjusted to pH 7.2 (for E. coli). Then, 3,3ʹ-dipropylthiadicarbocyanine (diSC3(5)) was 
added at 4 µM to the bacteria suspension and the mixture was incubated in the dark at room temperature (30 min 
for S. aureus and 60 min for E. coli). For E. coli only, KCl was then added at 100 mM, followed by EDTA at 
0.5 mM. Then, 100 µL aliquots of the bacterial suspension were added to wells of a 96-well plate (black with 
clear bottom); the fluorescence was tracked (ex: 620/10 nm, em: 670/10 nm) for approximately 8 min prior to 
exposure to the test compounds. The content of each well was then transferred to a different well containing 
100 µL of one of the various test compounds prepared at double the final test concentration. The fluorescence was 
then tracked for approximately 30 min. The final assay concentration of the test compounds was 32 µg/mL for S. 
aureus and 64 µg/mL for E. coli. UltraPure H2O was utilized as a negative control for both species. DMSO (20%) 
was utilized as a positive control for both species. Vancomycin (8 µg/mL) was used as a negative control for S. 
aureus and colistin (64 µg/mL) was used as positive control for E. coli. 
4.4.5. Cytoplasmic membrane permeabilization assay 
An inoculum containing 1.5 McFarland standard of mid-log cells (S. aureus ATCC 29213 or E. coli 
NCTC 10418) was suspended in either phosphate buffered saline (PBS – for S. aureus) or a 5 mM HEPES solution 
containing 20 mM glucose adjusted to pH 7.2 (for E. coli). Then, propidium iodide was added at 4 µM to the 
bacteria suspension and the mixture was incubated in the dark at room temperature (30 min for S. aureus and 60 
min for E. coli). For E. coli only, KCl was then added at 100 mM, followed by EDTA at 0.5 mM. Then, 100 µL 
aliquots of the bacterial suspension were added to wells of a 96-well plate (black with clear bottom); the 
fluorescence was tracked (ex: 544/10 nm, em: 615/10 nm) for approximately 8 min prior to exposure to the test 
compounds. The content of each well was then transferred to a different well containing 100 µL of one of the 
various test compounds prepared at double the final test concentration. The fluorescence was then tracked for 
approximately 30 min. The final assay concentration of the test compounds was 32 µg/mL for both S. aureus and 
E. coli. UltraPure H2O was utilized as a negative control for both species. Vancomycin (8 µg/mL) was used as a 
negative control for S. aureus and colistin (64 µg/mL) was used as a positive control for E. coli. 
 
4.5. In vivo murine model of CDI treatment 
 
4.5.1. Disease treatment model 
C. difficile spores from strain M7404 [46] were prepared for mouse infection experiments as previously 
described [45]. Animal handling and experimentation was performed in accordance with Victorian State 
Government regulations and approved by the Monash University Animal Ethics Committee (Monash University 
AEC no. MARP/2014/142). Groups of male, C57BL/6J, six week old mice (Walter and Eliza Hall Institute of 
Medical Research, Melbourne, Australia) were pre-treated with an antibiotic cocktail to induce susceptibility to 
infection as previously described [52]. Mice were administered 105 C. difficile spores by oral gavage. Six hours 
post-infection and then every 12 hours thereafter, mice were administered 2.5 mg (100 mg/kg in 10% DMSO) of 
the test compound, 10% DMSO or vancomycin (100 µL of a 4 mg/mL solution) by oral gavage. Mice were 
monitored daily for signs of disease (weight loss, diarrhoea, behavioural and physiological changes). Feces were 
collected 1 day post-infection to enumerate C. difficile spore load. Fecal pellets were resuspended in PBS (100 
mg/ml), heat shocked (30 minutes, 65 °C) and plated for spore enumeration as described previously [52]. Disease 
severity was assessed at 1 day post-infection by scoring the overall cage appearance (Table S1) as well as 
individual mouse fecal consistency (Table S2) and physiological appearance (Table S3). Mice were humanely 





4.5.2. Statistical analysis 
Statistical analysis was performed using Prism 7 (GraphPad Software). The Kaplan-Meier survival curves were 
assessed using a log-rank (Mantel-Cox) test. Weight loss, spore shedding, fecal consistency and physiological 
appearance data were analysed by one-way ANOVA with a post-hoc Tukeys multiple comparison test. 
Differences in data values were considered significant at a P value of < .05.  
 
4.6. Pharmacokinetics assay 
 
4.6.1. Mouse blood analysis 
 A 200 μL aliquot of the mouse blood was placed into a glass vial and diluted with phosphate buffered 
saline (PBS) solution (3.3 mL). The solution was vortexed for 20 s and then CH2Cl2 (3.5 mL) was added and the 
mixture was manually swirled to ensure adequate mixing with minimal emulsion formation. The layers were 
allowed to separate and the CH2Cl2 was removed by syringe. The aqueous blood layer was extracted again with 
another aliquot of CH2Cl2 (3.5 mL). The two extracts were combined and evaporated under reduced pressure to 
obtain an opaque residue. The residue was dissolved in MeOH (2.0 mL) with the aid of ultrasonication (30 s); the 
solution was filtered through a PTFE membrane filter (0.45 μm). The obtained solution was then subjected to 
LRMS analysis.   
 
4.6.2. Mouse blood analysis: procedure verification 
To ensure the mouse blood analysis procedure was sufficiently sensitive to detect small amounts of drug 
absorption, unadulterated mouse blood (i.e. blood from an untreated cohort) was doped with compound 67 and 
then subjected to the analysis procedure. The volume of mouse blood was accounted for to ensure that an accurate 
concentration representative of a 1% systemic bioavailability was achieved. To dope the blood with the correct 
concentration, 50 μL of a 0.05 mg/mL solution of compound 67 in 0.1% DMSO in H2O was added to the PBS 
diluent prior to completion of the analysis procedure. The blood/PBS/compound mixture was also allowed to rest 
for 2 h prior to extraction with CH2Cl2 and completion of the analysis procedure (Section 4.6.1.).  
 
4.6.3. Mouse feces analysis 
The obtained sample of mouse feces (from the cohort treated with compound 67) was added to a glass 
vial with CH2Cl2 (2.0 mL) and the mixture was stirred vigorously for 30 min. The solution was then filtered 
through a cotton plug and the solvent was removed under reduced pressure. The residue was taken up in MeOH 
(1.0 mL), sonicated for 30 s and then filtered through a PTFE membrane filter (0.45 μm). The obtained solution 
was then subjected to LRMS analysis.   
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